Valiltramiprosate

Valiltramiprosate
Clinical data
Other namesALZ-801; BLU8499
Legal status
Legal status
  • Investigational
Identifiers
  • 3-[[(2S)-2-amino-3-methylbutanoyl]amino]propane-1-sulfonic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC8H18N2O4S
Molar mass238.30 g·mol−1
3D model (JSmol)
  • CC(C)[C@@H](C(=O)NCCCS(=O)(=O)O)N
  • InChI=1S/C8H18N2O4S/c1-6(2)7(9)8(11)10-4-3-5-15(12,13)14/h6-7H,3-5,9H2,1-2H3,(H,10,11)(H,12,13,14)/t7-/m0/s1
  • Key:NRZRFNYKMSAZBI-ZETCQYMHSA-N

Valiltramiprosate is an investigational new drug that is being evaluated to treat early Alzheimer's disease.[1] It is an amyloid precursor protein antagonist.[2]

References

  1. ^ "Valiltramiprosate - Alzheon". AdisInsight. Springer Nature Switzerland AG.
  2. ^ Lee D, Antonsdottir IM, Clark ED, Porsteinsson AP (May 2024). "Review of valiltramiprosate (ALZ-801) for the treatment of Alzheimer's disease: a novel small molecule with disease modifying potential". Expert Opinion on Pharmacotherapy. 25 (7): 791–799. doi:10.1080/14656566.2024.2360069. PMID 38814590.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.